CN1686538A - Dendron shaped cell tumour vaccine for loading withered heat shock tumour cell, its preparation method and application - Google Patents
Dendron shaped cell tumour vaccine for loading withered heat shock tumour cell, its preparation method and application Download PDFInfo
- Publication number
- CN1686538A CN1686538A CN 200510038682 CN200510038682A CN1686538A CN 1686538 A CN1686538 A CN 1686538A CN 200510038682 CN200510038682 CN 200510038682 CN 200510038682 A CN200510038682 A CN 200510038682A CN 1686538 A CN1686538 A CN 1686538A
- Authority
- CN
- China
- Prior art keywords
- cell
- tumor
- heat shock
- dendritic cell
- tumor cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 169
- 230000035939 shock Effects 0.000 title claims abstract description 121
- 210000004027 cell Anatomy 0.000 title claims abstract description 84
- 229960005486 vaccine Drugs 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims description 35
- 238000011068 loading method Methods 0.000 title claims description 30
- 206010028980 Neoplasm Diseases 0.000 title abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 55
- 230000001939 inductive effect Effects 0.000 claims abstract description 23
- 210000004443 dendritic cell Anatomy 0.000 claims description 72
- 230000006907 apoptotic process Effects 0.000 claims description 69
- 208000017815 Dendritic cell tumor Diseases 0.000 claims description 47
- 239000001963 growth medium Substances 0.000 claims description 34
- 102000004127 Cytokines Human genes 0.000 claims description 27
- 108090000695 Cytokines Proteins 0.000 claims description 27
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 25
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 25
- 230000001640 apoptogenic effect Effects 0.000 claims description 21
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 20
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 20
- 210000005087 mononuclear cell Anatomy 0.000 claims description 19
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 17
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 14
- 210000005259 peripheral blood Anatomy 0.000 claims description 14
- 239000011886 peripheral blood Substances 0.000 claims description 14
- 230000000763 evoking effect Effects 0.000 claims description 13
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 10
- 108700012920 TNF Proteins 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 238000011953 bioanalysis Methods 0.000 claims description 8
- 108090000978 Interleukin-4 Proteins 0.000 claims description 6
- 102000004388 Interleukin-4 Human genes 0.000 claims description 6
- 101100372761 Mus musculus Flt1 gene Proteins 0.000 claims description 6
- 206010002660 Anoxia Diseases 0.000 claims description 5
- 241000976983 Anoxia Species 0.000 claims description 5
- 206010021143 Hypoxia Diseases 0.000 claims description 5
- 230000007953 anoxia Effects 0.000 claims description 5
- 210000004700 fetal blood Anatomy 0.000 claims description 5
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 4
- 102100040019 Interferon alpha-1/13 Human genes 0.000 claims description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 4
- 229940034982 antineoplastic agent Drugs 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 238000012136 culture method Methods 0.000 claims description 4
- 210000003003 monocyte-macrophage precursor cell Anatomy 0.000 claims description 4
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 47
- 108091007433 antigens Proteins 0.000 description 47
- 102000036639 antigens Human genes 0.000 description 47
- 238000004113 cell culture Methods 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- 239000012980 RPMI-1640 medium Substances 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 12
- 230000000890 antigenic effect Effects 0.000 description 11
- 201000009030 Carcinoma Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 9
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 9
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 230000009849 deactivation Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 8
- 108010058432 Chaperonin 60 Proteins 0.000 description 8
- 206010048612 Hydrothorax Diseases 0.000 description 8
- 230000002607 hemopoietic effect Effects 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 7
- 229920001917 Ficoll Polymers 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000037451 immune surveillance Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000012637 gene transfection Methods 0.000 description 3
- 102000046157 human CSF2 Human genes 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- -1 CD86 Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 101001036691 Homo sapiens Melanoma-associated antigen B4 Proteins 0.000 description 2
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102100039476 Melanoma-associated antigen B4 Human genes 0.000 description 2
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229940029030 dendritic cell vaccine Drugs 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000004719 natural immunity Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100031699 Choline transporter-like protein 1 Human genes 0.000 description 1
- 102100035954 Choline transporter-like protein 2 Human genes 0.000 description 1
- 102100039497 Choline transporter-like protein 3 Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000940912 Homo sapiens Choline transporter-like protein 1 Proteins 0.000 description 1
- 101000948115 Homo sapiens Choline transporter-like protein 2 Proteins 0.000 description 1
- 101000889279 Homo sapiens Choline transporter-like protein 3 Proteins 0.000 description 1
- 101100075865 Homo sapiens MAGEB4 gene Proteins 0.000 description 1
- 101001036692 Homo sapiens Melanoma-associated antigen B3 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 101150106914 LOX1 gene Proteins 0.000 description 1
- 101150014436 LOX1.1 gene Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102100039473 Melanoma-associated antigen B3 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 101150086211 OLR1 gene Proteins 0.000 description 1
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101100455173 Phaseolus vulgaris LOXA gene Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 101100182222 Solanum tuberosum LOX1.2 gene Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940041022 streptomycins Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 108010069784 vitespin Proteins 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510038682 CN1282485C (en) | 2005-04-04 | 2005-04-04 | Dendron shaped cell tumour vaccine for loading withered heat shock tumour cell, its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510038682 CN1282485C (en) | 2005-04-04 | 2005-04-04 | Dendron shaped cell tumour vaccine for loading withered heat shock tumour cell, its preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1686538A true CN1686538A (en) | 2005-10-26 |
CN1282485C CN1282485C (en) | 2006-11-01 |
Family
ID=35304580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510038682 Active CN1282485C (en) | 2005-04-04 | 2005-04-04 | Dendron shaped cell tumour vaccine for loading withered heat shock tumour cell, its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1282485C (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101461942B (en) * | 2008-08-27 | 2010-07-21 | 时宏珍 | Dendritic cell vaccine carrying recombinant human HSP70 polypeptide complexes, preparation method and application |
CN1887296B (en) * | 2006-07-31 | 2011-05-25 | 南京大学生物制药工程研究中心 | Method of inducing antitumor immunity and its application in preparing medicine |
CN102813916A (en) * | 2012-09-05 | 2012-12-12 | 北京希普生国际生物医学研究院 | Method for quickly preparing dentritic cell vaccine and application of dentritic cell vaccine |
CN102816792A (en) * | 2012-08-17 | 2012-12-12 | 南京大学 | Method for regulating expression, quantity and activity of heat shock protein 70 and application thereof |
CN104815323A (en) * | 2015-03-27 | 2015-08-05 | 北京康爱瑞浩生物科技股份有限公司 | Dendrite cell tumor vaccine and preparation method thereof |
CN106190977A (en) * | 2016-07-28 | 2016-12-07 | 深圳爱生再生医学科技有限公司 | Renal carcinoma therapeutic vaccine based on DC and preparation method thereof |
CN108392627A (en) * | 2018-03-20 | 2018-08-14 | 北京哲大生物科技有限公司 | The preparation method of DC-TAA tumor vaccines |
CN110283787A (en) * | 2019-07-25 | 2019-09-27 | 广州中医药大学(广州中医药研究院) | A kind of preparation method of dendritic cell tumor vaccine |
-
2005
- 2005-04-04 CN CN 200510038682 patent/CN1282485C/en active Active
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1887296B (en) * | 2006-07-31 | 2011-05-25 | 南京大学生物制药工程研究中心 | Method of inducing antitumor immunity and its application in preparing medicine |
CN101461942B (en) * | 2008-08-27 | 2010-07-21 | 时宏珍 | Dendritic cell vaccine carrying recombinant human HSP70 polypeptide complexes, preparation method and application |
CN102816792A (en) * | 2012-08-17 | 2012-12-12 | 南京大学 | Method for regulating expression, quantity and activity of heat shock protein 70 and application thereof |
CN102813916A (en) * | 2012-09-05 | 2012-12-12 | 北京希普生国际生物医学研究院 | Method for quickly preparing dentritic cell vaccine and application of dentritic cell vaccine |
CN104815323A (en) * | 2015-03-27 | 2015-08-05 | 北京康爱瑞浩生物科技股份有限公司 | Dendrite cell tumor vaccine and preparation method thereof |
CN104815323B (en) * | 2015-03-27 | 2018-03-13 | 北京康爱瑞浩生物科技股份有限公司 | A kind of dendritic cell tumor vaccine and preparation method thereof |
CN106190977A (en) * | 2016-07-28 | 2016-12-07 | 深圳爱生再生医学科技有限公司 | Renal carcinoma therapeutic vaccine based on DC and preparation method thereof |
CN108392627A (en) * | 2018-03-20 | 2018-08-14 | 北京哲大生物科技有限公司 | The preparation method of DC-TAA tumor vaccines |
CN110283787A (en) * | 2019-07-25 | 2019-09-27 | 广州中医药大学(广州中医药研究院) | A kind of preparation method of dendritic cell tumor vaccine |
CN110283787B (en) * | 2019-07-25 | 2023-07-07 | 广州中医药大学(广州中医药研究院) | Preparation method of dendritic cell tumor vaccine |
Also Published As
Publication number | Publication date |
---|---|
CN1282485C (en) | 2006-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1282485C (en) | Dendron shaped cell tumour vaccine for loading withered heat shock tumour cell, its preparation method and application | |
CN102268458B (en) | BA46 recombinant adeno-associated virus vector and construction method and application thereof | |
US9844508B2 (en) | Tumor vaccine and method for producing the same | |
CN1157560A (en) | Implanted device containing tumor cells for treatment of cancer | |
US9694059B2 (en) | Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases | |
US11642402B2 (en) | Method of producing immunotherapy vaccine | |
CN101461942B (en) | Dendritic cell vaccine carrying recombinant human HSP70 polypeptide complexes, preparation method and application | |
CN1921882A (en) | Allogeneic tumor therapeutic agent | |
CN101072582A (en) | Alpha thymosin peptides as cancer vaccine adjuvants | |
KR102060858B1 (en) | Vaccine delivery systems using yeast cell wall particles | |
CN108300692A (en) | A method of preparing HPV Antigen-specific cytotoxic T lymphocytes | |
CN105087647A (en) | Recombinant adeno-associated virus vector carrying survivin antigen genes and construction method and application thereof | |
CN1313151C (en) | Preparation of high-performance noncellular vaccine and usage | |
RU2333767C2 (en) | Vaccine compositions, methods for application thereof in melanoma prevention and treatment, and genetic constructions for obtaining active substances of composition | |
He et al. | Antitumor efficacy induced by a B16F10 tumor cell vaccine treated with mitoxantrone alone or in combination with reserpine and verapamil in mice | |
CN1842346A (en) | Regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor | |
Kreiter et al. | FLT3 ligand as a molecular adjuvant for naked RNA vaccines | |
CN1440812A (en) | Method of strengthening immune response with CD137 conjugated excitomotor | |
CN1709510A (en) | Vaccine composition containing modified dendritic cells | |
CN103495157A (en) | DC (Dendritic Cell) vaccine as well as preparation method and application thereof | |
US20090060946A1 (en) | Activation of antigen-specific T cells by virus/antigen-treated dendritic cells | |
CN1754576A (en) | Tumour cell vaccine preparation method | |
CN101773666A (en) | Therapeutic anticancer vaccine and preparation thereof | |
EP4206215A1 (en) | Ebv-targeted allogeneic b cell vaccine and preparation method therefor | |
CN106880833A (en) | Applications of the Antigenic Peptide RACGAP1 1 and RACGAP1 2 in treatment liver-cancer medicine is prepared |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Nanjing Dekang Biotechnology Co.,Ltd. Assignor: NANJING DALU INDUSTRIAL INVESTMENT GROUP Co.,Ltd. Contract fulfillment period: 2006.11.1 to 2025.4.4 Contract record no.: 2008320000981 Denomination of invention: Dendron shaped cell tumour vaccine for loading withered heat shock tumour cell, its preparation method and application Granted publication date: 20061101 License type: Exclusive license Record date: 20081015 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2006.11.1 TO 2025.4.4; CHANGE OF CONTRACT Name of requester: NANJING DEKANG BIOISYSTECH CO., LTD. Effective date: 20081015 |
|
ASS | Succession or assignment of patent right |
Owner name: NANJING DEKANG BIOISYSTECH CO., LTD. Free format text: FORMER OWNER: NANJING DALU INDUSTRY INVESTMENT GROUP CO.,LTD. Effective date: 20090424 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090424 Address after: 6 floor, Xincheng science and technology building, No. 69 Olympic Sports Avenue, Hexi New Town, Jianye District, Jiangsu, Nanjing, China Patentee after: Nanjing Dekang Biotechnology Co.,Ltd. Address before: No. 89, Pai Pai Road, Jiangning Economic Development Zone, Nanjing, Jiangsu Patentee before: NANJING DALU INDUSTRIAL INVESTMENT GROUP Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHI HONGZHEN Free format text: FORMER OWNER: NANJING DECON BIO-TECHNOLOGY CO., LTD. Effective date: 20110919 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210019 NANJING, JIANGSU PROVINCE TO: 211100 NANJING, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110919 Address after: Jiangning District of Nanjing City, Jiangsu province 211100 General Road No. 10, Tsinghua Yuan 58 Room 201 Patentee after: Shi Hongzhen Address before: 210019, 6 floor, Xincheng science and technology building, No. 69 Olympic Sports Avenue, Hexi New Town, Jianye District, Jiangsu, Nanjing Patentee before: Nanjing Dekang Biotechnology Co.,Ltd. |
|
EM01 | Change of recordation of patent licensing contract |
Change date: 20120326 Contract record no.: 2008320000981 Assignor after: Shi Hongzhen Assignor before: NANJING DALU INDUSTRIAL INVESTMENT GROUP Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: NANJING DECON BIO-TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHI HONGZHEN Effective date: 20130205 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 211100 NANJING, JIANGSU PROVINCE TO: 210019 NANJING, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130205 Address after: 210019, 6 floor, Xincheng science and technology building, No. 69 Olympic Sports Avenue, Hexi New Town, Jianye District, Nanjing, Jiangsu Patentee after: Nanjing Dekang Biotechnology Co.,Ltd. Address before: Jiangning District of Nanjing City, Jiangsu province 211100 General Road No. 10, Tsinghua Yuan 58 Room 201 Patentee before: Shi Hongzhen |
|
ASS | Succession or assignment of patent right |
Owner name: SHI HONGZHEN Free format text: FORMER OWNER: NANJING DECON BIO-TECHNOLOGY CO., LTD. Effective date: 20140221 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210019 NANJING, JIANGSU PROVINCE TO: 211100 NANJING, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140221 Address after: Jiangning district general road in Nanjing city Jiangsu province 211100 No. 10 Ping Tsinghua Yuan 58 Room 201 Patentee after: Shi Hongzhen Address before: 210019, 6 floor, Xincheng science and technology building, No. 69 Olympic Sports Avenue, Hexi New Town, Jianye District, Nanjing, Jiangsu Patentee before: Nanjing Dekang Biotechnology Co.,Ltd. |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Nanjing Dekang Biotechnology Co.,Ltd. Assignor: Shi Hongzhen Contract record no.: 2008320000981 Date of cancellation: 20140313 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20051026 Assignee: Jiangsu Kang Biotechnology Co.,Ltd. Assignor: Shi Hongzhen Contract record no.: 2014320000255 Denomination of invention: Dendron shaped cell tumour vaccine for loading withered heat shock tumour cell, its preparation method and application Granted publication date: 20061101 License type: Exclusive License Record date: 20140325 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU DECON BIO-SCI-TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHI HONGZHEN Effective date: 20140528 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 211100 NANJING, JIANGSU PROVINCE TO: 211899 NANJING, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140528 Address after: 211899, Jiangsu Province, Pukou District, Nanjing Pu Road, No. 28, building 1, new mile 5 Patentee after: Jiangsu Kang Biotechnology Co.,Ltd. Address before: Jiangning district general road in Nanjing city Jiangsu province 211100 No. 10 Ping Tsinghua Yuan 58 Room 201 Patentee before: Shi Hongzhen |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Jiangsu Kang Biotechnology Co.,Ltd. Assignor: Shi Hongzhen Contract record no.: 2014320000255 Date of cancellation: 20140504 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180917 Address after: 210000 B-6, Jiangsu science and Technology Park, 9 Wei Di Road, Qixia District, Nanjing, Jiangsu. Patentee after: De Kang cell bioengineering Center (Jiangsu) Co.,Ltd. Address before: 210000 room 208, block A, building 10, Spark Road, Pukou District, Nanjing, Jiangsu. Patentee before: Lu Anjun Effective date of registration: 20180917 Address after: 210000 room 208, block A, building 10, Spark Road, Pukou District, Nanjing, Jiangsu. Patentee after: Lu Anjun Address before: 211899 5, building 1, new mileage 28, Tianpu Road, Pukou District, Nanjing, Jiangsu, China Patentee before: Jiangsu Kang Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230110 Address after: Building B6-1, Jiangsu Life Science and Technology Innovation Park, No. 9, Weidi Road, Qixia District, Nanjing, Jiangsu, 210000 Patentee after: Jiangsu Kang Biotechnology Co.,Ltd. Address before: 210000 B-6, Jiangsu science and Technology Park, 9 Wei Di Road, Qixia District, Nanjing, Jiangsu. Patentee before: De Kang cell bioengineering Center (Jiangsu) Co.,Ltd. |
|
TR01 | Transfer of patent right |